AbbVie rises 3.3% as upbeat 2026 outlook and fresh analyst optimism lift sentiment

AbbVie (ABBV) is up 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to improving sentiment following AbbVie’s recent 2026 profit outlook and a wave of bullish analyst actions after strong performance from its newer immunology drugs. Shares may also be getting a lift ahead of management’s scheduled investor presentation later this week.

Details:

AbbVie issued full-year 2026 adjusted diluted EPS guidance of $14.37 to $14.57, which can reinforce confidence in earnings durability as the company navigates the post-Humira era.

An analyst upgrade to Buy from Neutral with a higher price target helped reset near-term expectations after the company’s recent quarterly update and guidance framework.

Management is scheduled to speak at the Bank of America Securities Healthcare Conference on May 13, 2026, which can act as a catalyst for positioning if investors expect incremental commentary on products, pipeline, or capital allocation.

This could also be a momentum follow-through from prior updates highlighting strong demand trends for key newer immunology medicines that are increasingly central to the growth narrative.

Sources:

AbbVie Investor Relations, AbbVie Newsroom, MarketBeat, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABBV Insider Trading Activity

$ABBV insiders have traded $ABBV stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:

PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 3 sales selling 18,668 shares for an estimated $4,375,549.
DAVID RYAN PURDUE (SVP, Controller) sold 5,230 shares for an estimated $1,221,518

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$ABBV Hedge Fund Activity

We have seen 1,800 institutional investors add shares of $ABBV stock to their portfolio, and 1,902 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 37,400,173 shares (-74.3%) from their portfolio in Q4 2025, for an estimated $8,545,565,528
FISHER ASSET MANAGEMENT, LLC added 8,463,716 shares (+1347.0%) to their portfolio in Q1 2026, for an estimated $1,832,648,425
CAPITAL WORLD INVESTORS added 6,736,161 shares (+106.3%) to their portfolio in Q4 2025, for an estimated $1,539,145,426
BLACKROCK, INC. added 5,197,454 shares (+3.6%) to their portfolio in Q4 2025, for an estimated $1,187,566,264
CARDANO RISK MANAGEMENT B.V. removed 4,908,260 shares (-90.1%) from their portfolio in Q1 2026, for an estimated $1,062,785,537
WELLINGTON MANAGEMENT GROUP LLP added 4,389,782 shares (+41.7%) to their portfolio in Q4 2025, for an estimated $1,003,021,289
GEODE CAPITAL MANAGEMENT, LLC added 4,190,487 shares (+10.4%) to their portfolio in Q4 2025, for an estimated $957,484,374

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABBV Government Contracts

We have seen $298,300 of award payments to $ABBV over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PROSTHETIC ORDER - IMPLANT ITEMS: $15,758
4568645077!NATRELLE TE SMOOTH 133S-MV-11-T: $9,109
4568672830!NATRELLE INSPIRA SCM 640CC BREAST IMPLAN: $9,021
PROSTHETICS:SURGICAL IMPLANTS BREAST RECONSTRUCTION: $8,468
4569321051!NATRELLE INSPIRA SCF 605CC BREAST IMPLAN: $4,014

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ABBV Congressional Stock Trading

Members of Congress have traded $ABBV stock 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ABBV Analyst Ratings

Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HSBC issued a "Buy" rating on 12/10/2025

To track analyst ratings and price targets for $ABBV, check out Quiver Quantitative's $ABBV forecast page.

$ABBV Price Targets

Multiple analysts have issued price targets for $ABBV recently. We have seen 11 analysts offer price targets for $ABBV in the last 6 months, with a median target of $260.0.

Here are some recent targets:

Gavin Clark-Gartner from Evercore ISI Group set a target price of $236.0 on 05/04/2026
Vamil Divan from Guggenheim set a target price of $249.0 on 05/01/2026
Carter Gould from Cantor Fitzgerald set a target price of $240.0 on 04/30/2026
Terence Flynn from Morgan Stanley set a target price of $278.0 on 04/30/2026
Gary Nachman from Canaccord Genuity set a target price of $265.0 on 04/30/2026
David Amsellem from Piper Sandler set a target price of $294.0 on 04/23/2026
Trung Huynh from RBC Capital set a target price of $260.0 on 02/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.